Autoimmune hepatitis beyond first-line therapy: management of intolerance and treatment failure
DOI:
https://doi.org/10.34119/bjhrv8n5-017Keywords:
autoimmune hepatitis, azathioprine, adverse eventAbstract
Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disease that, if untreated, may progress to advanced fibrosis, cirrhosis, and liver failure. While first-line therapy with corticosteroids and azathioprine (AZA) is standard worldwide, up to 20% of patients develop drug intolerance or fail to achieve complete biochemical remission despite optimized dosing. This mini review summarizes recent evidence for the management of intolerance and non-response in AIH, with focus on distinguishing adverse event–driven drug discontinuation from true pharmacologic failure. We discuss AZA-induced hepatotoxicity, the role of thiopurine metabolite profiling in optimizing therapy, and strategies for identifying preferential methylators. Second-line treatments, including mycophenolate mofetil, 6-mercaptopurine, thioguanine, and calcineurin inhibitors, are reviewed alongside emerging biologics such as rituximab and infliximab. This overview aims to provide clinicians with a concise, evidence-based update on therapeutic alternatives for difficult-to-treat AIH.
References
Chen Y, Chen R, Li H, Shuai Z. Clinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead. Immunol Res. 2025 Apr 7;73(1):67. doi: 10.1007/s12026-025-09622-9.
Covelli C, Sacchi D, Sarcognato S, Cazzagon N, Grillo F, Baciorri F, Fanni D, Cacciatore M, Maffeis V, Guido M. Pathology of autoimmune hepatitis. Pathologica. 2021 Jun;113(3):185-193. doi: 10.32074/1591-951X-241.
Iżycka-Świeszewska E, Walkusz N, Zieliński P, Sikorska K. Autoimmune hepatitis: clinicopathological characteristics and histopathological diagnosis in the light of current views. Clin Exp Hepatol. 2025 Mar;11(1):14-24. doi: 10.5114/ceh.2025.148233.
Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW; International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008 Jul;48(1):169-76. doi: 10.1002/hep.22322.
Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Zeniya M, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999 Nov;31(5):929-38. doi: 10.1016/s0168-8278(99)80297-9.
Couto CA, Terrabuio DRB, Cançado ELR, Porta G, Levy C, Silva AEB, Bittencourt PL; Members of the Pannel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Autoimmune Diseases of the Liver; Carvalho Filho RJ, Chaves DM, Miura IK, Codes L, Faria LC, Evangelista AS, Farias AQ, Gonçalves LL, Harriz M, Lopes EPA, Luz GO, Oliveira PMC, Oliveira EMG, Schiavon JLN, Sevá-Pereira T. Update Of The Brazilian Society Of Hepatology Recommendations For Diagnosis And Management Of Autoimmune Diseases Of The Liver. Arq Gastroenterol. 2019 Aug 13;56(2):232-241. doi: 10.1590/S0004-2803.201900000-43.
Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020 Aug;72(2):671-722. doi: 10.1002/hep.31065.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. J Hepatol. 2025 Aug;83(2):453-501. doi: 10.1016/j.jhep.2025.03.017.
Meng Z, Yang Y. Advances in the Treatment of Autoimmune Hepatitis. J Clin Transl Hepatol. 2024 Oct 28;12(10):878-885. doi: 10.14218/JCTH.2024.00193.
Snijders RJALM, Stoelinga AEC, Gevers TJG, Pape S, Biewenga M, Tushuizen ME, Verdonk RC, de Jonge HJM, Vrolijk JM, Bakker SF, Vanwolleghem T, de Boer YS, Baven Pronk MAMC, Beuers U, van der Meer AJ, Gerven NMFV, Sijtsma MGM, van Eijck BC, van IJzendoorn MC, van Herwaarden M, van den Brand FF, Korkmaz KS, van den Berg AP, Guichelaar MMJ, Levens AD, van Hoek B, Drenth JPH; Dutch Autoimmune Hepatitis Working Group. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis. J Hepatol. 2024 Apr;80(4):576-585. doi: 10.1016/j.jhep.2023.11.032.
Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 2008 May;7(3):319-33. doi: 10.1517/14740338.7.3.319.
Wunsch E, Krause L, Lohse AW, Schramm C, Löwe B, Uhlenbusch N, Snijders R, Willemse J, Janik M, Gevers TJG, Milkiewicz P. Non-Adherence to Standard Therapy in Autoimmune Hepatitis: Impact of Steroid Use and Over-the-Counter Medications. United European Gastroenterol J. 2025 Aug 1. doi: 10.1002/ueg2.70083.
Schwartz B, Al-Sabti R, Reau N. Late-Onset Acute Liver Injury From Azathioprine. ACG Case Rep J. 2022 Sep 7;9(9):e00847. doi: 10.14309/crj.0000000000000847.
Horning K, Schmidt C. Azathioprine-Induced Rapid Hepatotoxicity. J Pharm Technol. 2014 Feb;30(1):18-20. doi: 10.1177/8755122513504078.
Candels LS, Rahim MN, Shah S, Heneghan MA. Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates. J Hepatol. 2021 Aug;75(2):324-332. doi: 10.1016/j.jhep.2021.03.023.
Bolia R, Goel A, Srivastava A. Systematic Review and Meta-Analysis of Thiopurine Metabolite Levels and Biochemical Remission in Autoimmune Hepatitis. Ther Drug Monit. 2021 Oct 1;43(5):609-616.
Weltzsch JP, Bartel CF, Waldmann M, Renné T, Schulze S, Terziroli Beretta-Piccoli B, Papp M, Oo YH, Ronca V, Sebode M, Lohse AW, Schramm C, Hartl J. Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and co-therapy with allopurinol. Hepatology. 2024 Nov 1;80(5):1026-1040. doi: 10.1097/HEP.0000000000000940.
Reynolds NJ, Sinha A, Elias MS, Meggitt SJ. Translating translation into patient benefit for atopic eczema. Br J Dermatol. 2016 Oct;175 Suppl 2(Suppl Suppl 2):8-12. doi: 10.1111/bjd.14909.
Mercado LA, Gil-Lopez F, Chirila RM, Harnois DM. Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview. Diagnostics (Basel). 2024 Feb 9;14(4):382. doi: 10.3390/diagnostics14040382.
Heneghan MA, Lohse AW. Update in clinical science: Autoimmune hepatitis. J Hepatol. 2025 May;82(5):926-937. doi: 10.1016/j.jhep.2024.12.041.
Ergenc I, Heneghan MA Therapeutic pipeline for difficult-to-treat autoimmune hepatites. Frontline Gastroenterology Published Online First: 15 June 2025. doi: 10.1136/flgastro-2024-102925
Cardozo AJ, Van Drummond N, Longo A, Cancado E, Couto C, Faria L, Borgongino G, Rotman V, Evangelista A. Alternative therapies for difficult-to-treat autoimmune hepatitis: an experience of three Brazilian referral centers. Ann Hepatol. 2021;24(S1):100444. doi:10.1016/j.aohep.2021.100444.
Eldew H, Soldera J. Evaluation of biological therapies in autoimmune hepatitis: A case-based systematic review. World J Gastrointest Pathophysiol. 2025 Mar 22;16(1):101481. doi: 10.4291/wjgp.v16.i1.101481.
Weiler-Normann C, Schramm C, Quaas A, Wiegard C, Glaubke C, Pannicke N, Möller S, Lohse AW. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 2013 Mar;58(3):529-34. doi: 10.1016/j.jhep.2012.11.010.
Gökçe DT, Arı D, Kayhan MA, Efe C. A Case of Difficult-To-Treat Autoimmune Hepatitis Successfully Managed by Tofacitinib. Liver Int. 2025 Feb;45(2):e16173. doi: 10.1111/liv.16173.
Harputluoglu M, Caliskan AR, Akbulut S. Autoimmune hepatitis and liver transplantation: Indications, and recurrent and de novo autoimmune hepatitis. World J Transplant. 2022 Mar 18;12(3):59-64. doi: 10.5500/wjt.v12.i3.59.
